The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital.

Abstract

BACKGROUND Rituximab is a chimeric anti-CD20 human/mouse monoclonal antibody. As its usage has increased, there have been growing concerns about rituximab-related infusion-related reactions (IRRs). OBJECTIVE The aim of this study is to verify the clinical features and risk factors of IRRs by rituximab, and to help establish clinical guidelines for their… (More)
DOI: 10.1159/000357711

Topics

4 Figures and Tables

Cite this paper

@article{Jung2014TheIA, title={The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital.}, author={Jae-Woo Jung and Hye-Ryun Kang and Se Hoon Lee and Sang Heon Cho}, journal={Oncology}, year={2014}, volume={86 3}, pages={127-34} }